Zora Biosciences Oy specializes in the development of advanced diagnostic tests with a focus on cardiometabolic health. Utilizing mass spectrometry, the company identifies specific biomarkers associated with various diseases, which are then transformed into high-throughput clinical diagnostic tests. These tests are designed to provide valuable insights into cardiovascular health and metabolic conditions, and they are commercialized either through partnerships with international entities or via Zora's own reference laboratory located in Finland.

The company has developed several diagnostic tests targeting critical health issues. Notably, the CERT2 test assesses cardiovascular risk by measuring ceramide levels, which are believed to be more predictive of heart-related problems than traditional cholesterol metrics. Additionally, Zora has created the dSCORE test, which evaluates the risk of developing type 2 diabetes based on ceramide profiles. The company is also working on a diagnostic test for fatty liver disease, further expanding its portfolio in the cardiometabolic diagnostics space.

Finland

Zora Biosciences Oy is a diagnostics company that identifies markers of disease and develops them into robust high-throughput, value-added clinical methods, with a main focus on cardiovascular disease, offering the CERT - Coronary Event Risk Test.

Zora Biosciences

Company Details